ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b
Company profile
Ticker
IRWD
Exchange
Website
CEO
Mark Mallon
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Ironwood Pharmaceuticals Securities Corporation • Ironwood Pharmaceuticals GmbH • VectivBio AG • VectivBio Comet AG • GlyPharma Therapeutic Inc • VectivBio US, Inc. ...
IRS number
43404176
IRWD stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
16 Feb 24
8-K
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
15 Feb 24
8-K
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
8 Jan 24
UPLOAD
Letter from SEC
6 Dec 23
CORRESP
Correspondence with SEC
30 Nov 23
UPLOAD
Letter from SEC
15 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
S-8
Registration of securities for employees
9 Nov 23
S-3ASR
Automatic shelf registration
9 Nov 23
8-K
Ironwood Pharmaceuticals Reports Third Quarter 2023 Results
9 Nov 23
Transcripts
IRWD
Earnings call transcript
2023 Q4
15 Feb 24
IRWD
Earnings call transcript
2023 Q3
9 Nov 23
IRWD
Earnings call transcript
2023 Q2
8 Aug 23
IRWD
Earnings call transcript
2023 Q1
4 May 23
IRWD
Earnings call transcript
2023 Q1
4 May 23
IRWD
Earnings call transcript
2022 Q4
16 Feb 23
IRWD
Earnings call transcript
2022 Q3
3 Nov 22
IRWD
Earnings call transcript
2022 Q2
6 Aug 22
IRWD
Earnings call transcript
2022 Q1
8 May 22
IRWD
Earnings call transcript
2021 Q4
17 Feb 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 111.46 mm | 111.46 mm | 111.46 mm | 111.46 mm | 111.46 mm | 111.46 mm |
Cash burn (monthly) | 21.72 mm | 38.71 mm | (no burn) | 75.42 mm | (no burn) | (no burn) |
Cash used (since last report) | 145.14 mm | 258.65 mm | n/a | 503.98 mm | n/a | n/a |
Cash remaining | -33.68 mm | -147.19 mm | n/a | -392.52 mm | n/a | n/a |
Runway (months of cash) | -1.6 | -3.8 | n/a | -5.2 | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 247 |
Opened positions | 39 |
Closed positions | 41 |
Increased positions | 77 |
Reduced positions | 99 |
13F shares | Current |
---|---|
Total value | 1.45 tn |
Total shares | 158.74 mm |
Total puts | 304.00 k |
Total calls | 363.50 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 25.23 mm | $243.01 bn |
Sarissa Capital Management | 16.39 mm | $157.84 bn |
Vanguard | 14.90 mm | $143.45 bn |
STT State Street | 12.00 mm | $115.53 bn |
LSV Asset Management | 7.16 mm | $68.99 mm |
Renaissance Technologies | 5.80 mm | $55.79 bn |
Dimensional Fund Advisors | 5.52 mm | $53.13 bn |
Credit Suisse | 4.50 mm | $43.35 bn |
Victory Capital Management | 4.41 mm | $42.44 bn |
Brown Capital Management | 3.72 mm | $35.82 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Denner Alexander J | Class A Common Stock | Grant | Acquire A | No | No | 0 | 1,662 | 0.00 | 121,939 |
8 Mar 24 | Minardo John | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 32,752 | 0.00 | 311,975 |
8 Mar 24 | Minardo John | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 32,752 | 0.00 | 0 |
8 Mar 24 | Sravan Kumar Emany | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 37,120 | 0.00 | 338,853 |
8 Mar 24 | Sravan Kumar Emany | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 37,120 | 0.00 | 0 |
8 Mar 24 | Michael Shetzline | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 34,936 | 0.00 | 429,847 |
8 Mar 24 | Michael Shetzline | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 34,936 | 0.00 | 0 |
8 Mar 24 | Andrew Davis | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 37,120 | 0.00 | 310,756 |
8 Mar 24 | Andrew Davis | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 37,120 | 0.00 | 0 |
News
Ironwood Pharmaceuticals Announces Results From Phase 2 Exploratory STARGAZE Trial of Apraglutide For Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease
28 Mar 24
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In March
7 Mar 24
Wells Fargo Maintains Overweight on Ironwood Pharmaceuticals, Lowers Price Target to $14
1 Mar 24
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
29 Feb 24
12 Health Care Stocks Moving In Thursday's Intraday Session
29 Feb 24
Press releases
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
28 Mar 24
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
29 Feb 24
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
23 Feb 24
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
15 Feb 24
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
1 Feb 24